Search results for "Nyha class"

showing 7 items of 7 documents

Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation.

2021

AIMS We report the 2-year outcomes of the MitrAl ValvE RepaIr Clinical (MAVERIC) trial. Functional mitral regurgitation (FMR) is associated with poor outcomes for which there remains an unmet clinical need. ARTO is a transcatheter annular reduction device for the treatment of FMR and an emerging alternative for patients at high surgical risk. The MAVERIC trial was designed to evaluate the safety and performance of the ARTO system in FMR and heart failure (HF). METHODS AND RESULTS MAVERIC is an international multicentre, prospective, single arm study enrolling patients with FMR grade ≥ 2, New York Heart Association (NYHA) class ≥II symptoms despite maximal medical therapy. Patients were excl…

Heart FailureHeart Valve Prosthesis Implantationmedicine.medical_specialtyMitral valve repairMitral regurgitationPercutaneousbusiness.industrymedicine.medical_treatmentMitral Valve Insufficiencymedicine.diseaseNyha classmedicine.anatomical_structureTreatment OutcomeHeart failureInternal medicineMitral valvemedicineCardiologyHumansMitral ValveProspective StudiesCardiology and Cardiovascular MedicineAdverse effectbusinessFunctional mitral regurgitationEuropean journal of heart failureReferences
researchProduct

Preliminary Short-term Results of a Population of Patients Treated with MitraClip therapy: one Center Experience

2017

<p><span>Objectives: This retrospective analysis sought to evaluate 1-month outcomes and therapy effectiveness of a population of patients treated with MitraClip therapy. We describe in this article the preliminary results of primary effictiveness endpoint.</span></p><p><span>Background: Percutaneous Mitral Repair is being developed to treat severe mitral regurgitation (MR),with increasing real-world cases of functional MR(FMR). In the EVEREST(Endovascular Valve Edge-to-Edge Repair Study)II trial,percutaneous device showed superior safety but less reduction in MR at 1year. 4-year outcomes from EVEREST II trial showed no difference in the prevalence of mod…

Heart valvesmedicine.medical_specialtyeducation.field_of_studyMitral regurgitationlcsh:Diseases of the circulatory (Cardiovascular) systemPercutaneousbusiness.industryMitraClipPopulationlcsh:Rlcsh:MedicinePercutaneous approachNyha classNew york heart associationSurgerylcsh:RC666-701MedicineFunctional mrMitraClipbusinesseducationCatheter-based therapyNYHA functional classMitral RegurgitationInternational Cardiovascular Forum Journal
researchProduct

Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction

2015

Renal dysfunction (RD) and venous congestion are related and common in heart failure (HF). Studies suggest that venous congestion may be the primary driver of RD in HF. In this study, we sought to investigate retrospectively the relationship between common measures of renal function with caval congestion and mortality among outpatients with HF and RD. We reviewed data from 103 HF outpatients (45 males, mean age 74 years, ejection fraction 41.8 ± 11.6 %) with estimated glomerular filtration rate (eGFR) of 25.5 (adjusted OR 2.98, p 0.015) and eGFR ≤45.8 (adjusted OR 5.38, p 0.002) identify patients at risk for caval congestion; a BUN/Cr >23.7 was the best predictor of impaired collapsibility …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaRenal functionHyperemiaVena Cava InferiorHeart failureInferior vena cavaNyha classBlood Urea NitrogenCollapse index; Congestion; Heart failure; Inferior vena cava; Outpatients; Renal dysfunctionchemistry.chemical_compoundRisk FactorsInternal medicineInternal MedicinemedicineHumansRenal InsufficiencyInferior vena cavaBlood urea nitrogenAgedRetrospective StudiesCreatinineEjection fractionbusiness.industryOutpatientRetrospective cohort studymedicine.diseaseItalymedicine.veinchemistryCreatinineHeart failureCongestionEmergency MedicineCardiologyRenal dysfunctionFemaleCollapse indexbusinessBiomarkersGlomerular Filtration RateInternal and Emergency Medicine
researchProduct

Discordance in prognostic ability between physician assessed NYHA classification and self-reported health status in patients with acute heart failure

2021

Abstract Background Especially in patients with acute heart failure (AHF) the NYHA classification remains of uncertain representation of patients' actual health state. Alternatively, patient's subjective well-being, in terms of health-related quality of life (HRQL), showed to have an excellent prognostic ability in out clinic patients with chronic heart failure. Objectives It is unknown whether HRQL instruments can assess a more reliable prognostication in patients hospitalized due to AHF than the NYHA classification. Methods Goal Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC) was a multicenter, randomized, open-label blinded-end-point trial that em…

medicine.medical_specialtybusiness.industryInternal medicineHeart failureNYHA classificationMedicineIn patientCardiology and Cardiovascular Medicinebusinessmedicine.diseaseEuropean Heart Journal
researchProduct

Electrical Stimulation of Skeletal Muscles An Alternative to Aerobic Exercise Training in Patients With Chronic Heart Failure?

2006

The aim of this study was to investigate whether electrical stimulation of skeletal muscles could represent a rehabilitation alternative for patients with chronic heart failure (CHF). Thirty patients with CHF and NYHA class II-III were randomly assigned to a rehabilitation program using either electrical stimulation of skeletal muscles or bicycle training. Patients in the first group (n = 15) had 8 weeks of home-based low-frequency electrical stimulation (LFES) applied simultaneously to the quadriceps and calf muscles of both legs (1 h/day for 7 days/week); patients in the second group (n = 15) underwent 8 weeks of 40 minute aerobic exercise (3 times a week). After the 8-week period signifi…

medicine.medical_specialtybusiness.industryStimulationGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseNyha classSurgeryCalf muscles03 medical and health sciences0302 clinical medicineBlood pressureHeart failureAnesthesiaMedicineAerobic exerciseIn patientCardiology and Cardiovascular MedicinebusinessExercise duration030217 neurology & neurosurgeryInternational Heart Journal
researchProduct

Determinants of elevated carbohydrate antigen 125 in patients with severe symptomatic aortic valve stenosis referred for transcatheter aortic valve i…

2018

Elevated carbohydrate antigen 125 (CA125) predicts adverse outcome after transcatheter aortic valve implantation (TAVI). While known underlying pathophysiological mechanisms of elevated CA125 include serosal effusions and inflammatory stimuli, clinical determinants associated with elevated CA125 in patients referred for TAVI remain unknown. Therefore, we investigated clinical, laboratory and echocardiographic determinants of elevated CA125 in patients with severe aortic valve stenosis referred for TAVI.This study includes 650 patients with severe aortic stenosis referred for TAVI. Baseline CA125 was determined by an immunoassay and dichotomized (elevated versus normal) based on the manufact…

medicine.medical_specialtyendocrine system diseasesTranscatheter aorticAdverse outcomesHealth Toxicology and MutagenesisClinical Biochemistry030204 cardiovascular system & hematologyRisk AssessmentBiochemistryVentricular Function LeftNyha classTranscatheter Aortic Valve ReplacementHemoglobins03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineHumansMedicineIn patient030212 general & internal medicineAgedAged 80 and overbusiness.industryAortic Valve Stenosismedicine.diseaseTricuspid Valve Insufficiencyfemale genital diseases and pregnancy complicationsPathophysiologyStenosisC-Reactive ProteinCA-125 AntigenAortic valve stenosisCardiologybusinessCarbohydrate antigenBiomarkers
researchProduct

Clinical outcome of critically ill, not fully recompensated, patients undergoing MitraClip therapy

2014

Aims As periprocedural risk is low, MitraClip implantation is often performed in critically ill, not fully recompensated patients, who are in NYHA functional class IV at the time of the procedure, to accelerate convalescence. We herein sought to evaluate the procedural and 30-day outcome of this patient group. Methods and results A total of 803 patients undergoing MitraClip implantation were included in the German Mitral Valve Registry, and 30-day outcomes were prospectively assessed. Patients were separated based on NYHA functional class [(NYHA IV (n = 143), III (n = 572), and I/II (n = 88)]. No difference was noted in co-morbities and echocardiographic parameters of LV function between gr…

medicine.medical_specialtymedia_common.quotation_subject030204 cardiovascular system & hematologyNyha class03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineMitral valvemedicinecardiovascular diseases030212 general & internal medicinemedia_commonMitral regurgitationbusiness.industryCritically illMitraClipConvalescencemedicine.disease3. Good healthmedicine.anatomical_structureHeart failurecardiovascular systemCardiologyCardiology and Cardiovascular MedicinebusinessEuropean Journal of Heart Failure
researchProduct